课题基金 / 基金详情

High Throughput Screening for Biased Agonists of the TSH Receptor that Activate the Beta-arrestin pathway

High Throughput Screening for Biased Agonists of the TSH Receptor that Activate the Beta-arrestin pathway
高通量筛选激活 β-抑制蛋白途径的 TSH 受体偏向激动剂
批准号:
10688945
负责人:
Juan Marugan
金额:
$42.54万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

Juan Marugan的其他基金

相关文献

中文摘要
翻译
本项目的主要目标是开发一种有效的和选择性的小分子TSHR激动剂,具有偏性信号特征。 在此期间,从高通量筛选中鉴定出最有希望的命中物,并随后进行药物化学,合成了几个系列的类似物。用药物化学研究具有吸引人的活性特征的候选物,以合成一系列新的类似物,这些类似物被用于在TSHR过表达细胞系中进行测试,以确定β-Arrestin 1信号传导。对最有效、选择性和代谢稳定的分子进行了药代动力学研究。优化的先导分子正在骨质疏松症小鼠模型的有效性中进行评估。
英文摘要
The main goal of this project is to develop a potent and selective small molecule TSHR agonist, with biased signaling profile. During this period, the most promising hits from high-throughput screening were identified and followed up with medicinal chemistry and several series of analogs were synthesized. Candidates with attractive activity profiles were pursued with medicinal chemistry to synthesize a series of new analogs, which were advanced for testing in a TSHR overexpressing cell line to determine beta-Arrestin 1 signaling. Pharamcokinetics of the most potent, selective and metabolically stable molecules were carried out. The optimized lead molecule is under evaluation in efficacy mouse models of osteoporosis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Small molecule agonists of the relaxin 1 receptor
Identification of Small Molecule that act on gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome
Kinetic High Throughput Screening for Agonists and Inhibitors of the TRPML1 Ion channel
HTS Assay for Identification of Compounds that Reduce PNC Prevalence